Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 2
2007 3
2009 1
2016 1
2017 1
2018 4
2019 2
2020 9
2021 16
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

38 results
Results by year
Filters applied: . Clear all
Page 1
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Powles T, et al. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. Lancet Oncol. 2020. PMID: 32971005 Clinical Trial.
Lower risk of severe checkpoint inhibitor toxicity in more advanced disease.
Verheijden RJ, May AM, Blank CU, van der Veldt AAM, Boers-Sonderen MJ, Aarts MJB, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, van der Hoeven JJM, Hospers GAP, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, van Zeijl MCT, Wouters MWJM, Haanen JBAG, Kapiteijn E, Suijkerbuijk KPM. Verheijden RJ, et al. Among authors: piersma d. ESMO Open. 2020 Nov;5(6):e000945. doi: 10.1136/esmoopen-2020-000945. ESMO Open. 2020. PMID: 33199288 Free PMC article.
Real-world outcomes of advanced melanoma patients not represented in phase III trials.
van Zeijl MCT, Ismail RK, de Wreede LC, van den Eertwegh AJM, de Boer A, van Dartel M, Hilarius DL, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, Haanen JBAG, Wouters MWJM. van Zeijl MCT, et al. Among authors: piersma d. Int J Cancer. 2020 Dec 15;147(12):3461-3470. doi: 10.1002/ijc.33162. Epub 2020 Jul 4. Int J Cancer. 2020. PMID: 32559817 Free PMC article. Clinical Trial.
Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study.
van Zeijl MCT, Haanen JBAG, Wouters MWJM, de Wreede LC, Jochems A, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn EW, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van der Hoeven KJM, van den Eertwegh AJM. van Zeijl MCT, et al. Among authors: piersma d. J Immunother. 2020 Oct;43(8):256-264. doi: 10.1097/CJI.0000000000000334. J Immunother. 2020. PMID: 32804914
Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy.
Blankenstein SA, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, van den Eertwegh AJM, Franken MG, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, van Akkooi ACJ. Blankenstein SA, et al. Among authors: piersma d. Cancers (Basel). 2020 May 7;12(5):1176. doi: 10.3390/cancers12051176. Cancers (Basel). 2020. PMID: 32392717 Free PMC article.
Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs.
Leeneman B, Uyl-de Groot CA, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, Herbschleb KH, van der Hoeven JJM, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Haanen JBAG, Franken MG. Leeneman B, et al. Among authors: piersma d. Cancers (Basel). 2020 Apr 18;12(4):1003. doi: 10.3390/cancers12041003. Cancers (Basel). 2020. PMID: 32325748 Free PMC article.
Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status.
van Breeschoten J, Wouters MWJM, de Wreede LC, Hilarius DH, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Blokx WAM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, Boers MJ, van den Eertwegh AJM. van Breeschoten J, et al. Among authors: piersma d. Am J Clin Oncol. 2021 Feb 1;44(2):82-89. doi: 10.1097/COC.0000000000000786. Am J Clin Oncol. 2021. PMID: 33332931
LH receptor gene mutations and polymorphisms: an overview.
Piersma D, Verhoef-Post M, Berns EM, Themmen AP. Piersma D, et al. Mol Cell Endocrinol. 2007 Jan 2;260-262:282-6. doi: 10.1016/j.mce.2005.11.048. Epub 2006 Oct 9. Mol Cell Endocrinol. 2007. PMID: 17030087 Review. No abstract available.
Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry.
Verheijden RJ, May AM, Blank CU, Aarts MJB, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, Boers-Sonderen MJ, van der Hoeven JJM, Hospers GA, Piersma D, van Rijn RS, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van Zeijl MCT, Wouters MWJM, Haanen JBAG, Kapiteijn E, Suijkerbuijk KPM. Verheijden RJ, et al. Among authors: piersma d. Clin Cancer Res. 2020 May 1;26(9):2268-2274. doi: 10.1158/1078-0432.CCR-19-3322. Epub 2020 Jan 27. Clin Cancer Res. 2020. PMID: 31988197 Free article.
Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study.
van Zeijl MCT, Boer FL, van Poelgeest MIE, van den Eertwegh AJM, Wouters MWJM, de Wreede LC, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Kapiteijn EHW, Haanen JBAG. van Zeijl MCT, et al. Among authors: piersma d. Eur J Cancer. 2020 Sep;137:127-135. doi: 10.1016/j.ejca.2020.05.021. Epub 2020 Aug 4. Eur J Cancer. 2020. PMID: 32763783
38 results